Robert W. Baird Raises Twist Bioscience (NASDAQ:TWST) Price Target to $54.00

Twist Bioscience (NASDAQ:TWST) had its price target increased by research analysts at Robert W. Baird from $48.00 to $54.00 in a report released on Tuesday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Robert W. Baird’s price objective would suggest a potential upside of 0.63% from the company’s previous close.

Several other research analysts have also weighed in on TWST. Wolfe Research began coverage on shares of Twist Bioscience in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective on the stock. Barclays dropped their price target on shares of Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 19th. Scotiabank increased their price target on shares of Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, November 19th. Leerink Partners increased their price target on shares of Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research note on Thursday, October 17th. Finally, TD Cowen restated a “buy” rating and set a $58.00 price target on shares of Twist Bioscience in a research note on Tuesday, November 26th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $53.80.

Twist Bioscience Stock Performance

Twist Bioscience stock opened at $53.66 on Tuesday. The firm has a market cap of $3.19 billion, a PE ratio of -14.91 and a beta of 1.87. The firm’s 50 day moving average price is $48.74 and its two-hundred day moving average price is $46.27. Twist Bioscience has a twelve month low of $27.41 and a twelve month high of $60.90.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. The firm had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative net margin of 66.69% and a negative return on equity of 32.27%. The company’s revenue for the quarter was up 24.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.75) EPS. Equities analysts anticipate that Twist Bioscience will post -2.27 EPS for the current fiscal year.

Insider Activity at Twist Bioscience

In related news, SVP Paula Green sold 860 shares of the firm’s stock in a transaction on Friday, December 6th. The shares were sold at an average price of $52.70, for a total value of $45,322.00. Following the transaction, the senior vice president now directly owns 133,715 shares in the company, valued at approximately $7,046,780.50. This trade represents a 0.64 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Dennis Cho sold 806 shares of the stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $49.35, for a total transaction of $39,776.10. Following the completion of the sale, the insider now directly owns 112,221 shares of the company’s stock, valued at approximately $5,538,106.35. This trade represents a 0.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 59,002 shares of company stock worth $2,851,681. 3.01% of the stock is owned by insiders.

Institutional Trading of Twist Bioscience

A number of hedge funds have recently bought and sold shares of TWST. Van ECK Associates Corp lifted its holdings in shares of Twist Bioscience by 56.4% during the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after acquiring an additional 267 shares during the period. Signaturefd LLC increased its position in shares of Twist Bioscience by 63.0% during the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock worth $36,000 after purchasing an additional 306 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Twist Bioscience by 2.3% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 16,243 shares of the company’s stock valued at $734,000 after acquiring an additional 363 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Twist Bioscience by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after acquiring an additional 381 shares in the last quarter. Finally, US Bancorp DE increased its position in Twist Bioscience by 72.0% in the 4th quarter. US Bancorp DE now owns 1,436 shares of the company’s stock valued at $67,000 after acquiring an additional 601 shares in the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.